Elsevier
The theme for this year's World AIDS day is "EQUALIZE". We all need to address the inequalities which are holding back progress in ending AIDS.
Elsevier,
Neurobiology of Brain Disorders (Second Edition)
Biological Basis of Neurological and Psychiatric Disorders
2023, Pages 481-500
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by examining how various pathogens cause a variety of central nervous system (CNS) dysfunctions and the mechanisms of these changes.
Elsevier,
Translational Autoimmunity: Autoimmune Disease Associated with Different Clinical Features, Volume , 1 January 2022
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing the interplay between HIV infection and the immune system, the mechanisms it can generate autoimmunity, and an overview of the primary autoimmune diseases commonly diagnosed in patients with HIV infection.
Elsevier, Handbook of Sleep Disorders in Medical Conditions, Volume , 1 January 2019
Sleep health is a good indicator to a person’s overall health status and general well-being. Proper sleep is one of the most important factors to healthy immunity. Protecting and restoring sleep quality are vital to well-being. Problems such as insomnia, obstructive sleep apnea, fatigue, and hypersomnia can all affect the quality of a person’s sleep.
Elsevier,
Encyclopedia of Virology (Fourth Edition)
Volume 2, 2021, Pages 460-474
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by providing an overview of the viruses responsible for immunodeficiency syndromes like AIDS, highlighting their mechanism of action and targets for therapy.
Elsevier,
Advances in Virus Research, Volume 100, 1 January 2018
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by highlighting this unique role that HIV MTCT plays in understanding the immune correlates of protection and provide an overview of key aspects of MTCT including the epidemiology, transmission, and current prevention methods.
Elsevier,
Advances in Virus Research, Volume 95, 2016
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing the mechanisms of viral spread that are facilitated by cell–cell interactions and cell migration and discuss their implications for viral transmission, pathogenesis, and prevention.
Elsevier,
Advances in Virus Research, Volume 87, 2013
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by reviewing key advances in the field of neuropathogenesis and studies that have highlighted how molecular diversity within the HIV genome may impact HIV-associated neurologic disease.
Elsevier,
Advances in Virus Research, Volume 80, 2011
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by presenting a better understanding of how Nef disrupts antigen presentation may lead to the development of drugs that enhance the ability of the anti-HIV CTLs to control HIV disease.
Elsevier,
International Review of Cell and Molecular Biology, Volume 335, 2018
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by covering transcription regulation of human immunodeficiency virus type 1 (HIV-1) gene expression, focusing on the invaluable contributions, made by HIV research over the years, toward the field of transcription.
Elsevier,
International Review of Cell and Molecular Biology, Volume 328, 1 December 2017
This content aligns with Goal 3: Good Health as well as Goal 10: Reduced Inequalities by discussing the impact of chromatin structure on viral integration, transcriptional regulation and latency, and the host factors that influence HIV-1 replication by regulating chromatin organization.
Elsevier, eClinicalMedicine, Volume 53, November 2022
Background: Inequalities undermine efforts to end AIDS by 2030. We examined socioeconomic inequalities in the 90–90–90 target among people living with HIV (PLHIV) —men (MLHIV), women (WLHIV) and adolescents (ALHIV). Methods: We analysed the available Population HIV Impact Assessment (PHIA) survey data for each of the 12 sub-Saharan African countries, collected between 2015 and 2018 to estimate the attainment of each step of the 90–90–90 target by wealth quintiles.
Elsevier,
The Lancet HIV, Volume 9, July 2022
An Article in support of SDG 3, showing that in a sample of hospitalised people contributing data to the WHO Global Clinical Platform for COVID-19, HIV was an independent risk factor for both severe COVID-19 at admission and in-hospital mortality.
Elsevier,
eBioMedicine, Volume 80, June 2022
This Article supports SDG 3 by investigating the role of CD8+ T cell count on suppressive ART as a predictor of clinical progression in HIV, suggesting its potential use as a clinical biomarker in evaluations of novel therapies for ongoing immune dysfunction during treated infection.
Elsevier, The Lancet Child and Adolescent Health, Volume 6, June 2022
Background: There are 15·4 million children who are HIV-exposed and uninfected worldwide. Early child development crucially influences later academic and socioeconomic factors. However, the neurodevelopmental outcomes of HIV-exposed uninfected (HEU) children in the era of maternal antiretroviral therapy (ART) remain unclear. We aimed to examine the effects of in-utero exposure to HIV and ART on child neurodevelopment.
Elsevier,
The Lancet Planetary Health, Volume 6, April 2022, e359-e370
This Review supports SDGs 3 and 6, focusing on the complex ways that multiple factors interact during droughts to influence HIV treatment adherence. The authors suggest that economic and livelihood challenges resulting from food and water insecurity during droughts have the biggest impact on adherence.
Elsevier,
Blood Advances, Volume 6, 8 March 2022
Overall survival has improved for patients with HIV and TCLs such as AIDS-defining B-cell lymphomas in the last decade. Low CD4 cell count predicts poor overall survival in patients with HIV and TCL, emphasizing the need for effective antiretroviral therapy.
Elsevier,
The Lancet Healthy Longevity, Volume 3, March 2022
This Series paper supports SDGs 3 and 10, reviewing the intersectionality of HIV-related stigma and ageing-related stigma with health-related quality of life, suggesting that the intersectionality of stigmas creates a new inequality that is greater than the individual components.
Elsevier,
Blood, Volume 139, 17 February 2022
To date, most cancer clinical trials exclude all HIV-infected patients. The HIV Working Group has defined important principles related to eligibility criteria for HIV-infected patients with cancer. Notably, patients with CD4 count $350/mL should generally be eligible for any study, whereas lower CD4 count may be appropriate in the setting of second-line and later cancer therapy, assuming cART is carefully managed. All these studies will require multidisciplinary efforts.
Elsevier,
The Lancet Global Health, Volume 10, January 2022
An Article in support of SDG 3, showing that universal HIV testing and treatment improved employment outcomes and other indicators of socioeconomic wellbeing for HIV-positive adults and children in their households, but had no effect on HIV-negative adults.
Elsevier,
Blood Advances, Volume 5, 27 July 2021
We conducted a retrospective multicenter international analysis to identify prognostic factors, survival, and treatment-related outcomes in patients with HIV-BL contemporaneously treated. In this large collaborative effort, we analyzed a cohort of 249 patients with newly diagnosed HIV-BL treated at 35 centers in the United States and United Kingdom.
Elsevier,
The Lancet HIV, Volume 8, January 2021
A Review, in support of SDGs 3 and 17, summarising the efforts of a target product profile working group formed after the Sunnylands Summit: The Path Toward Ending HIV, in Feb 7–9, 2019, to develop target product profiles for HIV curative interventions.
Elsevier,
Blood Advances, Volume 5, 27 July 2021
We conducted a retrospective multicenter international analysis to identify prognostic factors, survival, and treatment-related outcomes in patients with HIV-BL contemporaneously treated. In this large collaborative effort, we analyzed a cohort of 249 patients with newly diagnosed HIV-BL treated at 35 centers in the United States and United Kingdom.
